Recursion Pharmaceuticals, Inc.

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
7.79 ^USD	-7.37%		-13.44%	-20.99%

Mar. 15	Recursion Pharmaceuticals Insider Sold Shares Worth $537,190, According to a Recent SEC Filing	MT
Mar. 11	Recursion Pharmaceuticals to Open London Office	MT

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals Insider Sold Shares Worth $537,190, According to a Recent SEC Filing	Mar. 15	MT
Recursion Pharmaceuticals to Open London Office	Mar. 11	MT
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat	Feb. 28	MT
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat	Feb. 28	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat	Feb. 28	MT
Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating	Feb. 28	MT
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q4 Revenue $10.9M	Feb. 27	MT
Recursion Pharmaceuticals, Inc. Appoints Kristen Rushton as Chief Business Operations Officer	Feb. 27	CI
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Recursion Pharmaceuticals Insider Sold Shares Worth $507,985, According to a Recent SEC Filing	Feb. 16	MT
Nvidia Discloses Stake in Tech Firms, Causing Shares to Rise	Feb. 15	MT
Nvidia Discloses Investment Stakes in AI Firms; Shares Jump	Feb. 15	MT
Let's move forward	Feb. 15
Arm, SoundHound AI shares jump as Nvidia builds stake	Feb. 15	RE
Recursion Pharmaceuticals Insider Sold Shares Worth $444,981, According to a Recent SEC Filing	Feb. 09	MT
Recursion Pharmaceuticals, Inc. Announces Transition of Shafique Virani from the Chief Business Officer into Senior Strategic Advisor	Feb. 07	CI
TD Cowen Starts Recursion Pharmaceuticals With Market Perform Rating	Jan. 26	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $517,508, According to a Recent SEC Filing	Jan. 19	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $396,214, According to a Recent SEC Filing	Jan. 12	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $273,202, According to a Recent SEC Filing	Jan. 12	MT
Recursion Unveils Lowe Drug Discovery Software At the J.P. Morgan Healthcare Conference	Jan. 08	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 04	MT
Sector Update: Health Care Stocks Gain Thursday Afternoon	Jan. 04	MT
Recursion Pharmaceuticals Shares Climb on Accord With Bayer for Possible Treatment of Fibrotic Diseases	Jan. 04	MT
Recursion Pharmaceuticals Shares Rise on Accord With Bayer for Possible Treatment of Fibrotic Diseases	Jan. 04	MT

Chart Recursion Pharmaceuticals, Inc.

Duration

Period

More charts

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Recursion Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.79 USD

Average target price

13 USD

Spread / Average Target

+66.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RECURSION PHARMACEUTICALS, INC.	-20.99%	1.83B
VERTEX PHARMACEUTICALS INCORPORATED	-2.34%	103B
REGENERON PHARMACEUTICALS, INC.	+2.31%	96.56B
ARGENX SE	+4.22%	22.61B
BIONTECH SE	-16.72%	21.18B
GENMAB A/S	-4.50%	19.07B
WUXI APPTEC CO., LTD.	-41.75%	16.53B
BEIGENE, LTD.	-23.26%	14.46B
NEUROCRINE BIOSCIENCES, INC.	-0.02%	13.25B
SAREPTA THERAPEUTICS, INC.	+22.69%	11.1B

Bio Therapeutic Drugs